Art Unit: 1635

## In the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

- 1. (Cancelled).
- 2. (Cancelled).
- 3. (Cancelled).
- 4. (Cancelled).
- 5. (Cancelled).
- 6. (Cancelled).
- 7. (Cancelled).
- 8. (Cancelled).
- 9. (Cancelled).
- 10. (Cancelled).
- 11. (Cancelled).
- 12. (Cancelled).
- 13. (Cancelled).
- 14. (Cancelled).
- 15. (Cancelled).
- 16. (Cancelled).
- 17. (Cancelled).
- 18. (Cancelled).
- 19. (Cancelled).
- 20. (Cancelled).
- 21. (Cancelled).

- 22. (Cancelled).
- 23. (Cancelled).
- 24. (Cancelled).
- 25. (Cancelled).
- 26. (New) A method for stimulating an immune response in a human comprising:

administering by a route selected from the group consisting of inhalation, ophthalmic, intranasal, parenteral, oral and intradermal to the human as an immunopotentiator an amount of a phosphorothioate oligonucleotide analog effective to stimulate an immune response, wherein the phosphorothioate oligonucleotide analog is not antisense.

- 27. (New) The method of claim 26, wherein the phosphorothioate oligonucleotide analog is an immunopotentiator of an antibody response.
  - 28. (New) The method of claim 26, wherein the human has cancer.
  - 29. (New) The method of claim 26, wherein the human has an infection.
  - 30. (New) The method of claim 26, wherein the human is having surgery.
- 31. (New) The method of claim 26, wherein the phosphorothicate oligonucleotide analog is formulated in a vehicle selected from the group consisting of liposomes and cationic lipids.
- 32. (New) The method of claim 26, wherein all of the internucleotide linkages of the phosphorothioate oligonucleotide analog are phosphorothioate linkages.
- 33. (New) The method of claim 26, wherein the phosphorothioate oligonucleotide analog includes at least one 2'-O-alkyl modification.

- 34. (New) The method of claim 26, wherein the 2'-O-alkyl modification is a 2'-O-methyl modification.
- 35. (New) The method of claim 26, wherein the 2'-O-alkyl modification is a 2'-O-propyl modification.
- 36. (New) The method of claim 26, further comprising administering a therapeutic modality, before, after or simultaneously with the phosphorothioate oligonucleotide analog.
- 37. (New) The method of claim 26, wherein the therapeutic modality is a drug.
- 38. (New) A method for stimulating a systemic or humoral immune response in a human comprising:

administering to the human as an immunopotentiator an amount of a phosphorothicate oligonucleotide analog formulated in a vehicle selected from the group consisting of liposomes and cationic lipids effective to stimulate the systemic or humoral immune response, wherein the phosphorothicate oligonucleotide analog is not antisense.

- 39. (New) The method of claim 38, wherein the phosphorothioate oligonucleotide analog is an immunopotentiator of an antibody response.
  - 40. (New) The method of claim 38, wherein the human has cancer.
  - 41. (New) The method of claim 38, wherein the human has an infection.
  - 42. (New) The method of claim 38, wherein the human is having surgery.
- 43. (New) The method of claim 38, wherein all of the internucleotide linkages of the phosphorothioate oligonucleotide analog are phosphorothioate linkages.

Art Unit: 1635

- 44. (New) The method of claim 38, wherein the phosphorothioate oligonucleotide analog includes at least one 2'-O-alkyl modification.
- 45. (New) The method of claim 38, wherein the 2'-O-alkyl modification is a 2'-O-methyl modification.
- 46. (New) The method of claim 38, wherein the 2'-O-alkyl modification is a 2'-O-propyl modification.
- 47. (New) The method of claim 38, further comprising administering a therapeutic modality, before, after or simultaneously with the phosphorothicate oligonucleotide analog.
- 48. (New) The method of claim 38, wherein the therapeutic modality is a drug.